Works by Rosenstock, Julio

Results: 311
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1221, doi. 10.1111/dom.14354
    By:
    • McCrimmon, Rory J.;
    • Al Sifri, Saud;
    • Emral, Rifat;
    • Mohan, Viswanathan;
    • Sauque‐Reyna, Leobardo;
    • Trescolí, Carlos;
    • Lalic, Nebojsa;
    • Alvarez, Agustina;
    • Demil, Nacima;
    • Coudert, Mathieu;
    • Shaunik, Alka;
    • Bonnemaire, Mireille;
    • Rosenstock, Julio
    Publication type:
    Article
    26
    27

    Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 569, doi. 10.1111/dom.14254
    By:
    • Espeland, Mark A.;
    • Pratley, Richard E.;
    • Rosenstock, Julio;
    • Kadowaki, Takashi;
    • Seino, Yutaka;
    • Zinman, Bernard;
    • Marx, Nikolaus;
    • McGuire, Darren K.;
    • Andersen, Knut Robert;
    • Mattheus, Michaela;
    • Keller, Annett;
    • Weber, Maria;
    • Johansen, Odd Erik
    Publication type:
    Article
    28
    29
    30

    Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1567, doi. 10.1111/dom.14068
    By:
    • Del Prato, Stefano;
    • Frias, Juan Pablo;
    • Blonde, Lawrence;
    • Aroda, Vanita R.;
    • Shehadeh, Niam;
    • Saremi, Aramesh;
    • Dex, Terry;
    • Niemoeller, Elisabeth;
    • Souhami, Elisabeth;
    • Liu, Minzhi;
    • Rosenstock, Julio
    Publication type:
    Article
    31
    32
    33

    Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1062, doi. 10.1111/dom.13995
    By:
    • Cooper, Mark E.;
    • Rosenstock, Julio;
    • Kadowaki, Takashi;
    • Seino, Yutaka;
    • Wanner, Christoph;
    • Schnaidt, Sven;
    • Clark, Douglas;
    • Johansen, Odd Erik
    Publication type:
    Article
    34

    Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 427, doi. 10.1111/dom.13945
    By:
    • Perkins, Bruce A.;
    • Soleymanlou, Nima;
    • Rosenstock, Julio;
    • Skyler, Jay S.;
    • Laffel, Lori M.;
    • Liesenfeld, Karl‐Heinz;
    • Neubacher, Dietmar;
    • Riggs, Matthew M.;
    • Johnston, Curtis K.;
    • Eudy‐Byrne, Rena J.;
    • Elmokadem, Ahmed;
    • George, Jyothis T.;
    • Marquard, Jan;
    • Nock, Valerie
    Publication type:
    Article
    35
    36

    Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
    By:
    • Aroda, Vanita R.;
    • Capehorn, Matthew S.;
    • Chaykin, Louis;
    • Frias, Juan P.;
    • Lausvig, Nanna L.;
    • Macura, Stanislava;
    • Lüdemann, Jörg;
    • Madsbad, Sten;
    • Rosenstock, Julio;
    • Tabak, Omur;
    • Tadayon, Sayeh;
    • Bain, Stephen C.
    Publication type:
    Article
    37
    38
    39
    40

    Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 12, p. 2821, doi. 10.1111/dom.13462
    By:
    • Rosenstock, Julio;
    • Handelsman, Yehuda;
    • Vidal, Josep;
    • Ampudia Blasco, F. Javier;
    • Giorgino, Francesco;
    • Liu, Minzhi;
    • Perfetti, Riccardo;
    • Meier, Juris J.
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide ( iGlarLixi) vs insulin glargine and lixisenatide monocomponents

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1798, doi. 10.1111/dom.12980
    By:
    • Davies, Melanie J.;
    • Leiter, Lawrence A.;
    • Guerci, Bruno;
    • Grunberger, George;
    • Ampudia‐Blasco, F. Javier;
    • Yu, Christine;
    • Stager, William;
    • Niemoeller, Elisabeth;
    • Souhami, Elisabeth;
    • Rosenstock, Julio
    Publication type:
    Article
    50